104 related articles for article (PubMed ID: 23047898)
1. p210bcr-abl induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1.
Rochelle T; Daubon T; Van Troys M; Harnois T; Waterschoot D; Ampe C; Roy L; Bourmeyster N; Constantin B
FASEB J; 2013 Jan; 27(1):123-34. PubMed ID: 23047898
[TBL] [Abstract][Full Text] [Related]
2. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
[TBL] [Abstract][Full Text] [Related]
3. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
Daubon T; Rochelle T; Bourmeyster N; Génot E
Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
[TBL] [Abstract][Full Text] [Related]
4. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
[TBL] [Abstract][Full Text] [Related]
5. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
7. Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Eitaki M; Yamamori T; Meike S; Yasui H; Inanami O
BMC Cancer; 2012 Oct; 12():469. PubMed ID: 23057787
[TBL] [Abstract][Full Text] [Related]
8. CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
Kubo K; Iwakami M; Muromoto R; Inagaki T; Kitai Y; Kon S; Sekine Y; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2015 Aug; 463(4):825-31. PubMed ID: 26102025
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells.
Neumann M; Wilisch A; Ma BC; Druker BJ; Serfling E; Franza BR
Anticancer Res; 1996; 16(3A):1075-83. PubMed ID: 8702216
[TBL] [Abstract][Full Text] [Related]
10. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.
Tala I; Chen R; Hu T; Fitzpatrick ER; Williams DA; Whitehead IP
Leukemia; 2013 Apr; 27(5):1080-9. PubMed ID: 23207522
[TBL] [Abstract][Full Text] [Related]
11. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
12. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
Zhu YF; Wang YZ; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
[TBL] [Abstract][Full Text] [Related]
13. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
14. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
16. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
[TBL] [Abstract][Full Text] [Related]
17. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL.
Salgia R; Brunkhorst B; Pisick E; Li JL; Lo SH; Chen LB; Griffin JD
Oncogene; 1995 Sep; 11(6):1149-55. PubMed ID: 7566975
[TBL] [Abstract][Full Text] [Related]
18. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome.
Kin Y; Li G; Shibuya M; Maru Y
J Biol Chem; 2001 Oct; 276(42):39462-8. PubMed ID: 11502748
[TBL] [Abstract][Full Text] [Related]
19. BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility.
Zheng X; Güller S; Beissert T; Puccetti E; Ruthardt M
BMC Cancer; 2006 Nov; 6():262. PubMed ID: 17090304
[TBL] [Abstract][Full Text] [Related]
20. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
